1-methoxy-4-methylcyclohexa-1,3-diene | 2161-94-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-methoxy-4-methylcyclohexa-1,3-diene
• 英文别名: 1,3-Cyclohexadiene, 1-methoxy-4-methyl-
• CAS: 2161-94-6
• 化学式: C₈H₁₂O
• 分子量: 124.183
• InChiKey: GASMMOOJZGEXKR-UHFFFAOYSA-N

物化性质

• 沸点：
  165-167 °C
• 密度：
  0.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-methoxy-4-methylcyclohexa-1,3-diene 生成 diethyl 2-[(1R)-1-methyl-4-oxocyclohex-2-en-1-yl]propanedioate
  参考文献：
  名称：

  光学活性三羰基（环己二烯基）铁（1+）盐：与空间定向的有机阳离子合成的等价物

  摘要：

  光学活性的三羰基（环己二烯基）铁（1+）盐I，II和III是由于与过渡金属的配位而具有分子不对称性的烯烃配合物。它们的反应用于指导最终形成已知绝对构型的新手性中心。定义了2-甲氧基-5-甲基盐I的绝对构型，描述了其在λ-二取代的环己烯酮的不对称合成中的应用。

  DOI：

  10.1016/0040-4039(81)80150-5
• 作为产物：
  描述：

  2,5-dihydro-4-methylanisole 在 potassium amide 作用下， 以 乙醚 、 氨 为溶剂， 反应 0.5h， 生成 1-methoxy-4-methylcyclohexa-1,3-diene
  参考文献：
  名称：

  Rao, G. S. R. Subba; Banerjee, D. K.; Devi, L. Uma, Australian Journal of Chemistry, 1992, vol. 45, # 1, p. 187 - 203

  摘要：

  DOI：

文献信息

• HIV protease inhibitors
  申请人：SmithKline Beechman Corp.

  公开号：US05438118A1

  公开（公告）日：1995-08-01

  Peptide mimics, having a constrained peptide backbone conformation, are HIV protease inhibitors. A compound of this invention is, for example, 3-Benzyl-5(alaninyl-1-aminoethyl)-2,3,6,7-tetrahydro-N-azepinyl-2-propiony l-valinyl-valinyl methyl ester.

  肽类模拟物，具有受限的肽骨架构象，是HIV蛋白酶抑制剂。该发明的化合物例如是3-苄基-5(丙氨酰-1-氨乙基)-2,3,6,7-四氢-N-氮杂环己基-2-丙酰基-缬氨酰-缬氨酰甲酯。
• Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents
  申请人：Duquesne University of the Holy Spirit

  公开号：US20160304525A1

  公开（公告）日：2016-10-20

  The present invention provides a compound of Formula I, and salts thereof, and a pharmaceutical composition comprising a compound of Formula I: wherein R 1 is selected from the group consisting of and R 2 is an alkyl group having from one to ten carbon atoms, or wherein R 2 is selected from the group consisting of R 1 is an alkyl group having from one to ten carbon atoms; and R is H, or an alkyl group having from one to ten carbon atoms, and R 3 is H, an alkyl group having from one to ten carbon atoms, or a halogen. Preferably the compound of Formula V includes wherein R 3 is a halogen, and most preferably wherein the halogen is chlorine. Methods of treating a patient with cancer with these compounds are also provided.

  本发明提供了一种化合物I的盐，以及包括化合物I的药物组合物：其中R1选自以下组成的群体，R2是具有一到十个碳原子的烷基基团，或者R2选自以下组成的群体，R1是具有一到十个碳原子的烷基基团；R是H，或者具有一到十个碳原子的烷基基团，R3是H，具有一到十个碳原子的烷基基团，或者卤素。优选化合物V包括其中R3是卤素，最优选其中卤素是氯。还提供了使用这些化合物治疗癌症患者的方法。
• Green electroluminescent compounds and organic electroluminescent device using the same
  申请人：Gracel Display Inc.

  公开号：EP2067766A1

  公开（公告）日：2009-06-10

  The present invention relates to novel organic electroluminescent compounds, organic electroluminescent devices and organic solar cells comprising the same. Specifically, the organic electroluminescent compounds according to the invention are represented by Chemical Formula (1) : wherein, R1 and R2 independently represent hydrogen, deuterium, linear or branched (C1-C20)alkyl, (C2-C20)alkenyl, (C2-C20)alkynyl, (C3-C15)cycloalkyl, tri(C1-C20)alkylsilyl, di(C1-C20)alkyl(C6-C20)arylsilyl, tri(C6-C20)arylsilyl, adamantyl, (C7-C15)bicycloalkyl or (C4-C20)heteroaryl, and the alkyl, alkenyl, alkynyl, cycloalkyl, trialkylsilyl, dialkylarylsilyl, triarylsilyl, adamantyl, bicycloalkyl or heteroaryl of R1 and R2 may be further substituted by one or more substituent(s) selected from deuterium, linear or branched (C1-C20)alkyl, (Cl-C20)alkenyl, (C1-C20)alkynyl, halogen, phenyl, fluorenyl, naphthyl and anthryl. The electroluminescent compounds according to the present invention are green electroluminescent compounds, of which the luminous efficiency and device lifetime have been maximized.

  本发明涉及新型有机电致发光化合物、含有该化合物的有机电致发光器件和有机太阳能电池。具体地，根据本发明的有机电致发光化合物由化学式（1）表示：其中，R1和R2独立地表示氢、氘、直链或支链（C1-C20）烷基、（C2-C20）烯基、（C2-C20）炔基、（C3-C15）环烷基、三（C1-C20）烷基硅基、二（C1-C20）烷基（C6-C20）芳基硅基、三（C6-C20）芳基硅基、金刚烷基、（C7-C15）双环烷基或（C4-C20）杂环芳基，而R1和R2的烷基、烯基、炔基、环烷基、三烷基硅基、二烷基芳基硅基、三芳基硅基、金刚烷基、双环烷基或杂环芳基可能进一步由氘、直链或支链（C1-C20）烷基、（Cl-C20）烯基、（C1-C20）炔基、卤素、苯基、芴基、萘基和蒽基中选择的一个或多个取代基所取代。根据本发明的电致发光化合物是绿色电致发光化合物，其发光效率和器件寿命已经最大化。
• IMIDAZOTHIAZOLE DERIVATIVES
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2103619A1

  公开（公告）日：2009-09-23

  There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity: wherein R1, R2, R3, R4, and R5 in the formula (1) each has the same meaning as defined in the specification.

  本发明提供了一种新型化合物，它能抑制小鼠双分 2（Mdm2）蛋白和 p53 蛋白之间的相互作用，并具有抗肿瘤活性。本发明提供了一种由下式（1）代表的咪唑噻唑衍生物，该衍生物具有各种取代基，可抑制 Mdm2 蛋白和 p53 蛋白之间的相互作用，并具有抗肿瘤活性： 其中，式（1）中的 R1、R2、R3、R4 和 R5 各具有与说明书中定义的相同含义。
• Pharmaceutical product
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2260869A2

  公开（公告）日：2010-12-15

  An agent for suppressing the production of various cytokines (IL-8 and the like) and inflammatory mediators, an agent for suppressing the expression of COX-II and the like, or an inhibitor of various phosphorylation enzymes (ATF2 and the like), which contains a TLR signaling inhibitory substance, preferably a compound represented by the formula (I) or the formula (II) wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  抑制各种细胞因子（IL-8 等）和炎症介质产生的制剂、抑制 COX-II 等表达的制剂或各种磷酸化酶（ATF2 等）的抑制剂，其中含有 TLR 信号抑制物质，最好是由式（I）或式（II）代表的化合物 其中各符号如说明书中所定义，或其盐或其原药。